Payment overview · 2025
General Payments
$1,328.96
47 reported records · 13 companies
Healthcare provider profile · identity verified
Luis E Valle, DO
Allopathic & Osteopathic Physicians|Internal Medicine · DOWNEY, CA · NPI 1497214431
Verified facts
What the public records show
CMS Open Payments records show Luis E Valle, DO received $1,328.96 in general payments during 2025 across 47 reported records.
Novo Nordisk Inc accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Qulipta, Rybelsus, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $283.26 | 21.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $213.65 | 16.1% | 9 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.16 | 11.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $154.78 | 11.7% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $132.47 | 10.0% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $130.87 | 9.8% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.84 | 3.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $49.77 | 3.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.50 | 3.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.30 | 2.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.21 | 2.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.33 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.82 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,328.96 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $283.26 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $158.16 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $142.95 | 5 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $132.47 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $115.75 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $98.92 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $93.46 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $87.06 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $84.22 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $50.36 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $49.84 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $49.77 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.86 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.86 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.50 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.30 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.21 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 118 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 162 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 83 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
83 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
118 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 317 | 124 |
| Metformin Hcl | Metformin Hcl | 256 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 91 |
| Diclofenac Sodium | Diclofenac Sodium | 231 | 70 |
| Losartan Potassium | Losartan Potassium | 203 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 198 | 89 |
| Gabapentin | Gabapentin | 195 | 89 |
| Jardiance | Empagliflozin | 162 | 43 |
| Lisinopril | Lisinopril | 162 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 59 |
| Famotidine | Famotidine | 131 | 59 |
| Farxiga | Dapagliflozin Propanediol | 118 | 33 |
| Omeprazole | Omeprazole | 114 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 49 |
| Montelukast Sodium | Montelukast Sodium | 105 | 46 |
| Furosemide | Furosemide | 101 | 43 |
| Glipizide | Glipizide | 98 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 37 |
| Linzess | Linaclotide | 83 | 25 |
| Alendronate Sodium | Alendronate Sodium | 78 | 39 |
| Ozempic | Semaglutide | 77 | 21 |
| Prednisone | Prednisone | 75 | 63 |
| Azithromycin | Azithromycin | 74 | 62 |
| Ibuprofen | Ibuprofen | 72 | 39 |
| Donepezil Hcl | Donepezil Hcl | 69 | 32 |
| Benazepril Hcl | Benazepril Hcl | 65 | 24 |
| Metformin Hcl Er | Metformin Hcl | 64 | 30 |
| Baclofen | Baclofen | 63 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 24 |
| Trazodone Hcl | Trazodone Hcl | 57 | 30 |
| Carvedilol | Carvedilol | 55 | 25 |
| Celecoxib | Celecoxib | 55 | 27 |
| Meloxicam | Meloxicam | 54 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 48 | 22 |
| Finasteride | Finasteride | 48 | 19 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 48 | 21 |
| Eliquis | Apixaban | 46 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 38 |
| Sertraline Hcl | Sertraline Hcl | 44 | 20 |
| Telmisartan | Telmisartan | 43 | 20 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 42 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 19 |
| Entresto | Sacubitril/Valsartan | 40 | 14 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 39 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 31 |
| Naproxen | Naproxen | 37 | 25 |
| Januvia | Sitagliptin Phosphate | 36 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 12 |
| Atenolol | Atenolol | 33 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 31 | 17 |
| Promethazine-Dm | Promethazine/Dextromethorphan | 31 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | 11 |
| Enalapril Maleate | Enalapril Maleate | 29 | 12 |
| Simvastatin | Simvastatin | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 24 |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 15 |
| Ezetimibe | Ezetimibe | 26 | 11 |
| Meclizine Hcl | Meclizine Hcl | 26 | 15 |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Qulipta | Atogepant | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | 11 |
| Chlorthalidone | Chlorthalidone | 20 | 11 |
| Licart | Diclofenac Epolamine | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 15 |
| Ondansetron Odt | Ondansetron | 19 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 14 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 15 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | 13 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ibu | Ibuprofen | 15 | 14 |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Spironolactone | Spironolactone | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | 13 |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,328.96 · 47 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CREON, Cologuard Collection Kit, FARXIGA, GEMTESA, GVOKE HYPOPEN, JARDIANCE, KISUNLA, KRYSTEXXA, Kerendia, LINZESS, MOUNJARO, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error